**Protocol for the Examination of Biopsy Specimens from Patients with Invasive Carcinoma of Renal Tubular Origin**

**Version:** 4.1.0.0

**Protocol Posting Date:** June 2021

The use of this protocol is recommended for clinical care purposes but is not required for accreditation purposes.

**This protocol should be used for the following procedures AND tumor types:**

|  |  |
| --- | --- |
| **Procedure** | **Description** |
| Biopsy | Includes specimens designated needle biopsy, incisional biopsy (wedge), and others |
| **Tumor Type** | **Description** |
| Renal cell carcinomas | Includes all renal cell carcinoma variants |

**This protocol is NOT required for accreditation purposes for the following:**

|  |
| --- |
| **Procedure** |
| Resection (consider Kidney Resection protocol) |
| **Tumor Type** |
| Urothelial tumors (consider Ureter, Renal Pelvis protocol) |
| Wilm’s tumors (Consider Wilm’s Tumor protocol) |
| Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols) |
| Sarcoma (consider the Soft Tissue protocol) |

**Authors**

John R. Srigley, MD\*; Gladell P. Paner, MD\*; Ming Zhou, MD, PhD\*; Lara R. Harik, MD; Robert Allan, MD; Mahul B. Amin, MD; Steven C. Campbell, MD; Anthony Chang, MD; Brett Delahunt, MD; David J. Grignon, MD; Peter A. Humphrey, MD, PhD; Bradley C. Leibovich, MD; Rodolfo Montironi, MD; Jason Pettus, MD; Victor E. Reuter, MD.

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.  
\* Denotes primary author.

**Accreditation Requirements**

The use of this case summary is recommended for clinical care purposes but is not required for accreditation purposes. The core and conditional data elements are routinely reported. Non-core data elements are indicated with a plus sign (+) to allow for reporting information that may be of clinical value.

**Summary of Changes**

**v 4.1.0.0**

* General Reformatting
* New Tumor Site Section
* Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign

**Reporting Template**

**Protocol Posting Date: June 2021**

**Select a single response unless otherwise indicated.**

**CASE SUMMARY: (KIDNEY: Biopsy)**

**Standard(s)**: AJCC-UICC 8

*This case summary is recommended for reporting biopsy specimens, but is not required for accreditation purposes.*

**SPECIMEN**

**Procedure**

\_\_\_ Needle biopsy

\_\_\_ Incisional biopsy, wedge

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not specified

**Specimen Laterality**

\_\_\_ Right

\_\_\_ Left

\_\_\_ Not specified

**TUMOR**

**Tumor Site (select all that apply)**

\_\_\_ Upper pole

\_\_\_ Middle

\_\_\_ Lower pole

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not known

**Histologic Type (Note** [**A**](#2128)**)**

\_\_\_ Clear cell renal cell carcinoma

\_\_\_ Multilocular cystic clear cell renal cell neoplasm of low malignant potential

\_\_\_ Papillary renal cell carcinoma

\_\_\_ Papillary renal cell carcinoma, Type 1

\_\_\_ Papillary renal cell carcinoma, Type 2

\_\_\_ Chromophobe renal cell carcinoma

\_\_\_ Collecting duct carcinoma

\_\_\_ Renal medullary carcinoma

\_\_\_ MiT family translocation renal cell carcinoma

\_\_\_ Xp11 translocation renal cell carcinoma

\_\_\_ t(6;11) renal cell carcinoma

\_\_\_ Mucinous tubular and spindle renal cell carcinoma

\_\_\_ Tubulocystic renal cell carcinoma

\_\_\_ Acquired cystic disease associated renal cell carcinoma

\_\_\_ Clear cell papillary renal cell carcinoma

\_\_\_ Hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma

\_\_\_ Succinate dehydrogenase (SDH) deficient renal carcinoma

\_\_\_ Renal cell carcinoma, unclassified

\_\_\_ Other histologic type not listed (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Histologic Type Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Histologic Grade (WHO / ISUP) (Note** [**B**](#2130)**)**

\_\_\_ G1 (nucleoli absent or inconspicuous and basophilic at 400x magnification)

\_\_\_ G2 (nucleoli conspicuous and eosinophilic at 400x magnification, visible but not prominent at 100x magnification)

\_\_\_ G3 (nucleoli conspicuous and eosinophilic at 100x magnification)

\_\_\_ G4 (extreme nuclear pleomorphism and / or multi-nuclear giant cells and / or rhabdoid and / or sarcomatoid differentiation)

\_\_\_ GX (cannot be assessed)

\_\_\_ Not applicable: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Sarcomatoid Features (Note** [**C**](#2129)**)**

\_\_\_ Not identified

\_\_\_ Present

**+Percentage of Sarcomatoid Element**

\_\_\_ Specify percentage : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined

\_\_\_ Cannot be determined

**Rhabdoid Features (Note** [**C**](#2129)**)**

\_\_\_ Not identified

\_\_\_ Present

\_\_\_ Cannot be determined

**+Necrosis (Note** [**D**](#2131)**)**

\_\_\_ Not identified

\_\_\_ Present

**+Lymphovascular Invasion**

\_\_\_ Not identified

\_\_\_ Present

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Tumor Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**ADDITIONAL FINDINGS**

**+Additional Findings**

\_\_\_ None identified

\_\_\_ Other pathology present (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**COMMENTS**

**Comment(s): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Explanatory Notes**

**A. Histologic Type**

The current World Health Organization (WHO) classification (2016) is based on the International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia 2012.[1,](#8166)[2](#8167)

Clear cell renal cell carcinoma

Multilocular clear cell renal cell neoplasm of low malignant potential

Papillary renal cell carcinoma

Type 1

Type 2

Chromophobe renal cell carcinoma

Collecting duct carcinoma

Renal medullary carcinoma

MiT family translocation renal cell carcinoma

Mucinous tubular and spindle cell carcinoma

Tubulocystic renal cell carcinoma

Acquired cystic disease associated renal cell carcinoma

Clear cell papillary/tubulopapillary renal cell carcinoma

Hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma

Succinate dehydrogenase (SDH) deficient renal carcinoma

Renal cell carcinoma, unclassified

Papillary adenoma

Renal oncocytoma

Many subtypes of renal cell carcinoma, including many newly described variants, have differing clinical behaviors and prognosis.[1,](#8166)[2,](#8167)[3,](#8168)[4](#8169) Additionally the usage of adjuvant therapy is related to tumor subtype.[5](#8170)The concept of an emerging/provisional category of renal cell carcinoma was introduced in the 2012 ISUP Vancouver classification.[2](#8167) These tumors, while appearing distinctive, had not been fully characterized morphologically or by ancillary techniques. This category in the 2016 WHO classification includes the following entities: oncocytoid renal cell carcinoma (RCC) postneuroblastoma, thyroid-like follicular RCC, anaplastic lymphoma kinase (ALK) rearrangement-associated RCC, and RCC with (angio) leiomyomatous stroma.[1](#8166) For the purpose of the protocol, these emerging tumors should be classified under “other” and the name specified.

Occasionally more than 1 histologic type of carcinoma occurs within the same kidney specimen. Each tumor type should be separately recorded along with its associated prognostic factors.[6](#8171)

References

1. Humphrey PA, Moch H, Reuter VE, Ulbright TM, eds. World Health Organization (WHO) Classification of Tumours: Pathology and Genetics of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016.
2. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol. 2013;37:1469-1489.
3. Murphy WM, Grignon DJ, Perlman EJ, eds. Tumours of the Kidney, Bladder, and Related Urinary Structures. AFIP Atlas of Tumour Pathology. Series 4. Washington, DC: American Registry of Pathology; 2004.
4. Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol. 2009;22:S2-S23.
5. O'Brien MF, Russo P, Motzer RJ. Sunitinib therapy in renal cell carcinoma. BJU Int. 2008;101:1339-1342.
6. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25:275-278.

**B. Histologic Grade**

The WHO/ISUP grading system has supplanted the Fuhrman system as the grading standard.[1,](#8179)[2](#8180)  This grading system has been validated for both clear cell and papillary renal cell carcinoma; however, it has not been validated for other RCC subtypes.[3,](#8181)[4](#8182) Nevertheless, the WHO/ISUP grade may be included for descriptive purposes.  Currently it is recommended that chromophobe renal cell carcinoma not be graded with the WHO/ISUP system. Details are shown below:

Not applicable

Grade X- Cannot be assessed

Grade 1 - Nucleoli absent or inconspicuous and basophilic at 400x magnification

Grade 2 - Nucleoli conspicuous and eosinophilic at 400x magnification, visible but not prominent at 100x magnification

Grade 3 - Nucleoli conspicuous and eosinophilic at 100x magnification

Grade 4 - Extreme nuclear pleomorphism and/or multinuclear giant cells and/or rhabdoid and/or sarcomatoid differentiation

Although the grading system does reference the tinctorial characteristics of the nucleoli, the determining feature is the nucleolar prominence. Grade should be assigned based on the single high-power field showing the greatest degree of pleomorphism.

References

1. Humphrey PA, Moch H, Reuter VE, Ulbright TM, eds. World Health Organization (WHO) Classification of Tumours: Pathology and Genetics of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016.
2. Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490-1504.
3. Sika-Paotonu D, Bethwaite PB, McCredie MRE, Jordan TW, Delahunt B. Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol. 2006;30:1091-1096.
4. Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Am J Surg Pathol. 2011;135:1134-1139.

**C. Sarcomatoid and Rhabdoid Features**

Sarcomatoid carcinoma is not a specific morphogenetic subtype of renal cell carcinoma but is considered as a pattern of dedifferentiation.[1,](#8172)[2,](#8173)[3,](#8174)[4](#8175)  Sarcomatoid change in a renal cell carcinoma is associated with an adverse outcome.[1,](#8172)[4](#8175) Sarcomatoid morphology may be found in any histologic subtypes of renal cell carcinomas, including clear cell, papillary, chromophobe, collecting duct, and other rare and unclassified subtypes.[1,](#8172)[2,](#8173)[3,](#8174)[4](#8175) When the background carcinoma subtype is recognized, it should be specified under histologic type (see Note A). Pure sarcomatoid carcinoma or sarcomatoid carcinoma associated with epithelial elements that do not conform to usual renal carcinoma cell types should be considered as unclassified renal cell carcinoma. Sarcomatoid morphology is also incorporated into the WHO/ISUP grading system as grade 4.

There is some indication that the percentage of sarcomatoid component in a renal cell carcinoma has prognostic importance.[2,](#8173)[4](#8175)

Rhabdoid features, like sarcomatoid, are a characteristic of high-grade disease. Rhabdoid cells have abundant eosinophilic cytoplasm with an eccentric nucleus often with a prominent nucleolus.[4,](#8175)[5,](#8176)[6,](#8177)[7](#8178) Rhabdoid changes are associated with an adverse outcome and in cases with rhabdoid morphology, about 25% of them also show sarcomatoid features).[1](#8172) Rhabdoid morphology is an important component of the new WHO/ISUP grading system (grade 4).[4](#8175)  No solid evidence exists on the prognostic significance of the extent of rhabdoid morphology.[1](#8172)

References

1. Humphrey PA, Moch H, Reuter VE, Ulbright TM, eds. World Health Organization (WHO) Classification of Tumours: Pathology and Genetics of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016.
2. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25:275-278.
3. Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28:435-441.
4. Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490-1504.
5. Kuroiwa K, Kinoshita Y, Shiratsuchi H, et al. Renal cell carcinoma with rhabdoid features: an aggressive neoplasm. Histopathology. 2002;41:538-548.
6. Gokden N, Nappi O, Swanson PE, et al. Renal cell carcinoma with rhabdoid features. Am J Surg Pathol. 2000;24:1329-1338.
7. Leroy X, Zini L, Buob D, et al. Renal cell carcinoma with rhabdoid features. Arch Pathol Lab Med. 2007;131:102-106.

**D. Necrosis**

Tumor necrosis is an important prognostic factor in renal cell carcinoma.[1,](#8183)[2,](#8184)[3](#8185) It is recommended that both macroscopic and microscopic (coagulative) necrosis be recorded. The prognostic significance of necrosis independent of tumor stage has been identified in clear cell and chromophobe renal cell carcinoma[2](#8184). The prognostic significance of necrosis in papillary renal cell carcinoma is controversial. Large papillary carcinomas not uncommonly display cystic necrosis and yet don’t exhibit extra renal spread. Tumor necrosis as a prognostic factor cannot be assessed in a situation where patients have undergone presurgical arterial embolization.

At present, the prognostic significance of the extent of necrosis is unclear; however, it is recommended that this be recorded as a percentage.[3](#8185)

References

1. Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490-1504.
2. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparison of outcome and prognostic features among histologic suptypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612-624.
3. Klatte T, Said JW, de Martino M, et al. Presence of tumour necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. J Urol. 2009;181:1558-1564.